Sullo Maria Giuseppa, Perri Domenico, Sibilio Michelina, Rafaniello Concetta, Fucile Annamaria, Rossi Francesco, Capuano Annalisa
Department of Experimental Medicine, Section of Pharmacology, Pharmacoepidemiology and Pharmacovigilance Centre of the Campania Region, Second University of Naples, Naples, Italy.
Department of Pediatric, Moscati Hospital, Aversa, Italy.
J Pharmacol Pharmacother. 2015 Jan-Mar;6(1):45-8. doi: 10.4103/0976-500X.149148.
Nebivolol is a third-generation beta blocker that exerts selective antagonistic activity on β1 receptors. It has vasodilating properties that result from direct stimulation of endothelial nitric oxide synthase. Nebivolol is indicated for the treatment of hypertension and heart failure, and is generally well tolerated. In this article, we report a case of an infant who was admitted to the Pediatrics and Neonatology Unit of the Moscati Hospital (Aversa, Italy) about 24 hours after birth. The reason for hospitalization was persistent severe hypoglycemia (blood glucose = 30 mg/dL) and jaundice (total bilirubin = 12.5 mg/dL, indirect bilirubin 11.75 mg/dL). He was born by spontaneous delivery after a normal term pregnancy. Birth weight was 3040 g and the Apgar score was 6-9. The mother reported taking nebivolol 5 mg/day for unspecified tachycardia in the last 4 months of pregnancy. Clinical and instrumental investigations carried out during hospitalization did not reveal any congenital or perinatal abnormalities. After treatment for metabolic and electrolyte imbalance, he was discharged on the 10(th) day of hospitalization, in good clinical condition and with normalization of clinical and laboratory parameters. Currently, there are no specific studies on nebivolol tolerability during pregnancy. Our data suggest that the risk profile of nebivolol during pregnancy is the same as that of other β-blockers. Therefore, further studies are required to determine the safety of β-blockers during pregnancy and the risks to the unborn child.
奈必洛尔是一种第三代β受体阻滞剂，对β1受体具有选择性拮抗活性。它具有血管舒张特性，这是由直接刺激内皮型一氧化氮合酶所致。奈必洛尔适用于治疗高血压和心力衰竭，且一般耐受性良好。在本文中，我们报告了一例婴儿病例，该婴儿出生后约24小时被收治入意大利阿韦尔萨市莫斯卡蒂医院的儿科和新生儿科。住院原因是持续性严重低血糖（血糖 = 30 mg/dL）和黄疸（总胆红素 = 12.5 mg/dL，间接胆红素11.75 mg/dL）。他是足月正常妊娠后顺产出生。出生体重3040 g，阿氏评分6 - 9分。母亲报告在妊娠最后4个月因不明原因的心动过速每天服用5 mg奈必洛尔。住院期间进行的临床和仪器检查未发现任何先天性或围产期异常。在对代谢和电解质失衡进行治疗后，他于住院第10天出院，临床状况良好，临床和实验室参数均恢复正常。目前，尚无关于妊娠期间奈必洛尔耐受性的具体研究。我们的数据表明，妊娠期间奈必洛尔的风险状况与其他β受体阻滞剂相同。因此，需要进一步研究以确定β受体阻滞剂在妊娠期间的安全性以及对未出生胎儿的风险。
